lyophilized peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-12. Anything still debated is marked as such rather than presented as settled.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
For the use of hormone antagonists in cancer, see hormonal therapy (oncology) A hormone antagonist is a molecule, produced either synthetically or endogenously, that binds to a specific hormone receptor to block the effect or synthesis of that hormone. There are many types of hormone antagonists, such as gonadotropin-releasing hormone (GnRH) antagonists, estrogen antagonists, and androgen antagonists. Organisms may use hormone antagonists to modify the action of their hormone receptors. For example, ghrelin is a hormone that stimulates appetite and growth hormone release by activating the growth hormone secretagogue receptor (GHSR). LEAP2 was found to be a peptide hormone synthesized by the liver and small intestine that blocks the GHSR activation by ghrelin, thereby reducing appetite. Synthetically produced hormone antagonists can also be used as anticancer treatments for hormone-sensitive cancers like breast cancer and prostate cancer.
==== Eating more vegetables ==== Fruits and vegetables have been shown to increase satiety and decrease hunger signals. These food groups have a low energy density, mainly due to the high water content and partly due to the fiber content. The reduction of energy density has been shown to enhance satiety. The water content adds satisfying weight without excess calories and fiber slows gastric emptying. Studies have also shown that fiber decreases hunger and also decreases total energy intake.
Immunoaffinity chromatography uses the specific binding of an antibody-antigen to selectively purify the target protein. The procedure involves immobilizing a protein to a solid substrate (e.g. a porous bead or a membrane), which then selectively binds the target, while everything else flows through. The target protein can be eluted by changing the pH or the salinity. The immobilized ligand can be an antibody (such as immunoglobulin G) or it can be a protein (such as protein A). Because this method does not involve engineering in a tag, it can be used for proteins from natural sources.
== Sequence conservation and stability == Due to the prevalent and unwavering nature of rRNA across all organisms, the study of its resistance to gene transfer, mutation, and alteration without destruction of the organism has become a popular field of interest. Ribosomal RNA genes have been found to be tolerant to modification and incursion. When rRNA sequencing is altered, cells have been found to become compromised and quickly cease normal function. These key traits of rRNA have become especially important for gene database projects (comprehensive online resources such as SILVA or SINA) where alignment of ribosomal RNA sequences from across the different biologic domains greatly eases "taxonomic assignment, phylogenetic analysis and the investigation of microbial diversity." Examples of resilience:
Sources: en.wikipedia.org
== Archaeological investigation == The site was discovered in 1982 when a team led by Francis Pryor carried out a survey of dykes in the area funded by English Heritage. In 1992 Pryor told National Geographic that he "stumbled – literally – upon' Flag Fen 'when he tripped on a piece of wood lying in the bottom of a drainage ditch." Excavation commenced in the Summer of 1984 and by 1990 had revealed vertical and horizontal timbers, animal bones, a bronze dagger and other metal items and fragments, flint implements and 400 potsherds. Further finds included items imported from continental Europe and the oldest surviving wooden wheel found in England, dating from 1300 BC. In 2012 DigVentures ran the world's first crowdfunded excavation, raising £30,000 to enable a three-week excavation at Flag Fen. The site had experienced a 50% decline in visitors since the large-scale English Heritage-funded excavations had finished in 1995. The project's remit was to help revitalise the heritage attraction whilst providing detailed scientific information on the preservation of the waterlogged timbers. The project involved around 250 members of the public from 11 countries, supported by a specialist team including partners from the British Museum, Durham University, Birmingham University, York Archaeological Trust, University College London and English Heritage to assist in the scientific investigations. 130 members of public received hands-on training in archaeological techniques on site and visitor numbers increased by 29% from the previous year.
This procedure can induce ovulation, typically leads to a single pregnancy, but other risks may be higher compared to medication. The procedure might lead to lower chance of live births compared to medication alone. Ovarian wedge resection is no longer used as much due to complications such as adhesions and the presence of frequently effective medications. As a final treatment option, in vitro fertilisation (IVF) can be considered. IVF does increase the risk of ovarian hyperstimulation syndrome. Using a 'freeze all' strategy makes it easier to transfer a single embryo and provides time for the ovaries to recover from hyperstimulation. A less effective alternative, but with much lower risks of ovarian hyperstimulation syndrome, is in vitro maturation instead of full IVF. This option avoids high-dose gonadotropin therapy.
== See also == Breast-feeding Breastfeeding and fertility Epileptic seizure Hyperprolactinaemia Hypothalamic–pituitary–prolactin axis Male lactation Prolactin modulator Prolactin receptor Prolactin-releasing hormone Prolactinoma Weaning
== Emulsifiers == An emulsifier is a substance that stabilizes an emulsion by reducing the oil-water interface tension. Emulsifiers are a part of a broader group of compounds known as surfactants, or "surface-active agents". Surfactants are compounds that are typically amphiphilic, meaning they have a polar or hydrophilic (water-soluble) part and a non-polar (hydrophobic or lipophilic) part. Emulsifiers that are more soluble in water (and, conversely, less soluble in oil) will generally form oil-in-water emulsions, while emulsifiers that are more soluble in oil will form water-in-oil emulsions. The following are examples of food emulsifiers:
=== α - cleavage === Fragmentation arises from a homolysis processes. This cleavage results from the tendency of the unpaired electron from the radical site to pair up with an electron from another bond to an atom adjacent to the charge site, as illustrated below. This reaction is defined as a homolytic cleavage since only a single electron is transferred. The driving forces for such reaction is the electron donating abilities of the radical sites: N > S, O,π > Cl, Br > H. An example is the cleavage of carbon-carbon bonds next to a heteroatom. In this depiction, single-electron movements are indicated by a single-headed arrow.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.